A new drug from Bristol Myers Squibb called Cobenfy has been approved by the FDA as a novel treatment for schizophrenia, offering better tolerability for patients. The drug targets muscarinic cholinergic receptors in the brain, providing a new approach to treating the disorder. Developed by Karuna Therapeutics, Cobenfy showed significant reductions in schizophrenia symptoms in clinical trials. While the drug is priced at $1,850 per month, analysts predict peak sales of $2 billion in 2030. Competing drugs targeting similar receptors are also in development, with AbbVie’s emraclidine likely to seek approval in 2025. Despite some drawbacks, Cobenfy’s unique mechanism of action is seen as a promising new option for patients.
Source link
FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades
